Who is moving to which position
Resolved 27 March 2026Incoming appointee
2 itemsDeparting officer
2 itemsThe candidate has held senior positions at several major global companies in the healthcare industry and has extensive international experience and a strong track record. Through experience as an outside director, the candidate has also developed independent, objective and highly informed judgment. The candidate is expected to contribute to strengthening the Board of Directors’ oversight and decision-making functions, achieving long-term growth in the global medtech market, and maximizing corporate value., The candidate has extensive experience as a chief financial officer at several global healthcare companies and as an Australian Chartered Accountant, as well as board experience at other companies, providing global and highly specialized expertise and broad knowledge. The candidate is expected to contribute to strengthening the Board of Directors’ oversight and decision-making functions, sustainable growth and the long-term enhancement of corporate value.
| Item | Details |
|---|---|
| Resolution date | 27 March 2026 |
| Scheduled Appointment Date | After approval at the annual general meeting of shareholders scheduled for June 2026 (the specific effective date is not disclosed) |
| Name of appointee | Jean-Luc Butel (ジャン＝リュック・ブテル), Costa Saroukos (コスタ・サルウコス) |
| Appointee's new position | Outside Directors, Outside Directors |
| Appointee's previous position | Global Healthcare Advisor and President, K8 Global Pte. Ltd. (current); Outside Director, Takeda Pharmaceutical Company Limited (current), among others, Chairman of the Board, Mitsubishi Tanabe Pharma Corporation (currently T a n a b e P h a r m a Corporation) (current); Independent Outside Director, CSL Limited (current) |
| Appointee's date of birth | 8 November 1956, 15 April 1971 |
| Number of shares held by the appointee | 0 shares (as of 30 September 2025), 0 shares (as of 30 September 2025) |
| Name of departing officer | Takeuchi Yasuo (竹内 康雄), Okubo Toshihiko (大久保 俊彦) |
| Former position of departing officer | Director and Representative Executive Officer, Directors |
| Reasons for appointment | The candidate has held senior positions at several major global companies in the healthcare industry and has extensive international experience and a strong track record. Through experience as an outside director, the candidate has also developed independent, objective and highly informed judgment. The candidate is expected to contribute to strengthening the Board of Directors’ oversight and decision-making functions, achieving long-term growth in the global medtech market, and maximizing corporate value., The candidate has extensive experience as a chief financial officer at several global healthcare companies and as an Australian Chartered Accountant, as well as board experience at other companies, providing global and highly specialized expertise and broad knowledge. The candidate is expected to contribute to strengthening the Board of Directors’ oversight and decision-making functions, sustainable growth and the long-term enhancement of corporate value. |
| Number of directors after the change | 11 directors (including 10 outside directors) |
| Subject to Approval by the General Meeting of Shareholders | Required. The company plans to submit an agenda item for the election of director candidates at the annual general meeting of shareholders scheduled for June 2026 (the scheduled meeting date has not been specifically disclosed). |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it expects the new candidates to strengthen the Board of Directors’ oversight and decision-making functions and contribute to sustainable growth and enhanced corporate value by drawing on their international experience, expertise and board experience in the healthcare industry. No reason for the retirement of the outgoing directors was stated.